Regulation of mRNA translation by estrogen receptor in breast cancer.
Breast cancer
Estrogen receptor
Protein synthesis
mRNA translation
mTOR
Journal
Steroids
ISSN: 1878-5867
Titre abrégé: Steroids
Pays: United States
ID NLM: 0404536
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
27
07
2023
revised:
15
09
2023
accepted:
28
09
2023
medline:
27
11
2023
pubmed:
9
10
2023
entrez:
8
10
2023
Statut:
ppublish
Résumé
Breast cancer is one of the leading causes of cancer-related fatalities and the most often diagnosed malignancy in women globally. Dysregulation of sex hormone signaling pathways mediated by the estrogen receptor (ER) in breast cancer is well characterized. Although ER is known to promote cell growth and survival by altering gene transcription, recent research suggests that its effects in cancers are also mediated through dysregulation of protein synthesis. This implies that ER can coordinately affect gene expression through both translational and transcriptional pathways, leading to the development of malignancy. In this review, we will cover the current understanding of how the ER controls mRNA translation in breast cancer and discuss any potential clinical implications of this phenomenon.
Identifiants
pubmed: 37806603
pii: S0039-128X(23)00144-7
doi: 10.1016/j.steroids.2023.109316
pii:
doi:
Substances chimiques
Receptors, Estrogen
0
Estrogen Antagonists
0
Estrogen Receptor alpha
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109316Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.